Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics.

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...